Innovation Economics and Management Research (IEMR)
Volume 11, Issue 1 (2026). ISSN：2949-1304

Analysis of the Application of Artificial Intelligence Technology in the Clinical Management of Depression

Ran Li[1], Jianchuan Chi[2]

[1] School of Marxism, Qilu University of Technology, Ji'nan 250353, China
[2] School of History and Culture, Shandong Normal University, Ji'nan 250358, China

ABSTRACT
Depression, as one of the mental disorders with the heaviest global disease burden, is confronted with the "three lows" predicament of low recognition rate, low treatment rate and high recurrence rate in clinical management. The development of artificial intelligence (AI) technology has provided a brand-new paradigm for breaking this deadlock. The application status and technical paths of AI in the entire process of "screening - diagnosis - treatment - management" of depression were systematically explored: In the early identification and screening stage, AI integrates scale data, physiological indicators, digital footprints and multimodal information, significantly enhancing the early warning capability; In the diagnosis and differentiation stage, AI-assisted structured interviews and quantitative evaluations, combined with neuroimaging and peripheral biomarkers, achieve precise differentiation. In the field of therapy, AI has driven individualized medication decisions, digital psychotherapy, and parameter optimization in physical therapy. In the prognosis management and recurrence prevention stage, AI has achieved a transformation from intermittent follow-up to continuous monitoring through remote monitoring, dynamic recurrence risk prediction, and self-management support systems. The role of AI should be positioned as "enhancing intelligence". In the future, the integrated model of "human-machine collaboration" is expected to drive mental health services towards a more predictive, preventive, personalized and participatory direction, ultimately serving the well-being and dignity of patients.

Keywords: *artificial intelligence; depression; clinical management*

1. INTRODUCTION

Depression is a severe mental disorder characterized by persistent low mood, reduced interest and cognitive dysfunction[1].According to the World Health Organization, approximately 280 million people worldwide are affected by it, and the disease burden it causes ranks among the top in the world. However, the clinical management of depression has long been plagued by the predicament of "two lows and one high" : low identification rate, low treatment rate, and high recurrence rate. The traditional management model is highly dependent on patients' subjective reports and doctors' clinical experience, resulting in obvious efficiency bottlenecks in every link from early screening to long-term follow-up.

The leapfrog development of artificial intelligence technology, especially the breakthroughs in machine learning, deep learning and large language models, has provided a brand-new technological paradigm for solving the above-mentioned predicament. AI can efficiently process massive, high-dimensional, and unstructured medical data, uncovering subtle patterns that are hard for the human eye to detect - from the spectral features of voice, micro-expression changes on the face, to behavioral trajectories on social media, and functional connection abnormalities in neuroimaging.[2]This shift from macroscopic symptoms to microscopic digital phenotypes is reshaping the clinical management logic of depression. By systematically exploring the application status, technical core and clinical value of AI in the entire chain of "screening - diagnosis - treatment - management" of depression, it is expected to provide a clear roadmap for subsequent research and clinical transformation.

2. APPLICATION OF AI IN THE EARLY IDENTIFICATION AND SCREENING OF DEPRESSION

Early identification is the "golden window" for the management of depression. However, in primary care and community Settings, a large number of patients are missed due to atypical symptoms or being masked by somatization symptoms. AI technology is breaking through this bottleneck by expanding the dimensions and accuracy of screening.

2.1 Intelligent screening based on scales and questionnaires

Traditional self-rating scales, such as the Patient Health Questionnaire (PHQ-9), although widely used, are vulnerable to recall bias and social desirability. The intervention of AI is not merely about electronicization; rather, it has achieved "dynamic" and "adaptive" screening. Computer Adaptive Testing (CAT) based on Item Response Theory (IRT) can adjust subsequent questions in real time according to patients' responses to the first few items. Under the premise of ensuring reliability and validity, it can shorten the assessment time by more than 50%. Even more cutting-edge is that natural language processing (NLP) technology is being used to analyze the responses to open-ended questionnaires. For instance, through semantic embedding analysis, AI can capture the underlying sense of despair or anhedonia in patients' word choices, which are often masked in structured scales. In addition, by integrating the unstructured text of clinical electronic medical records (EMR), the AI model can automatically extract keywords and emotional tendencies related to depression through named entity recognition (NER), achieving an unobstructed initial screening of large-scale asymptomatic populations. Its sensitivity has already reached over 0.85.

2.2 Recognition based on physiological indicators

AI turns physiological signals into objective "Windows" of emotional states. At the neurophysiological level, electroencephalogram (EEG) has attracted much attention due to its high temporal resolution and portability. Deep learning models can extract specific frequency bands and nonlinear features from resting-state EEGs to distinguish between depressed patients and healthy controls, with an accuracy rate of 80% to 90%. At the peripheral physiological level, the heart rate variability (HRV), skin electrical activity (EDA), and body surface temperature continuously monitored by wearable devices, after being modeled by random forest or support vector machine (SVM), can reflect autonomic nerve dysfunction, the core pathophysiological change of depression. Research has confirmed that AI models based on circadian HRV rhythm disorders can warn of the risk of depressive episodes on average four weeks before clinical diagnosis.

2.3 Screening based on digital footprints and behavioral data

Human behavior leaves behind "breadcrumbs" in the digital age, and AI makes it a projection of mental states. The passive metadata of smartphones implies clues of social withdrawal and psychomotor delay. For example, a decrease in location entropy (with a fixed range of activity) and a sharp drop in social app usage duration have been shown to be significantly correlated with the severity of depression (PHQ-9 score). In addition, subtle features of speech and facial expressions are equally crucial. The AI model can analyze the speech features of patients when reading text aloud, as well as facial action units (AU) in semi-structured interviews, such as drooping corners of the mouth and reduced activity of the orbicularis oculi muscle. This screening model based on behavioral digital phenotypes has shown high convergent validity with clinical diagnosis.

2.4 Early warning based on multimodal fusion

Single mode information has limitations, and multimodal fusion is the key path to achieve high-precision early warning. Fusion strategies are mainly divided into three categories: early fusion, mid fusion, and late fusion. Currently, late fusion has been proven to be more robust. A typical warning system will simultaneously input: 1) PHQ-2 simplified scale score; 2) Sleep activity rhythm over the past 7 days (wristband data); 3) Emotional inclination score of social media texts[3]. Subsequently, a multi-layer perceptron (MLP) or gradient boosting tree is used for risk level classification. In preliminary studies, the area under the curve of multimodal models often reaches 0.90 or more, significantly better than any single modal model. This provides a feasible technical solution for achieving a "layered and progressive" screening of community populations.

3. THE APPLICATION OF AI IN THE DIAGNOSIS AND DIFFERENTIATION OF DEPRESSION

Diagnosis is a prerequisite for treatment. There is significant heterogeneity in the current symptomatic diagnostic criteria based on DSM-5 or ICD-11. The intervention of AI aims to provide more objective and accurate auxiliary evidence for clinical diagnosis.

3.1 AI assisted clinical diagnosis

3.1.1 Intelligent assistance for structured clinical interviews

Traditional clinical interviews rely on doctors to capture symptom criteria in real time and are vulnerable to memory bias and fatigue. AI tools can serve as a "second pair of eyes". For instance, a real-time speech transcription and analysis system based on NLP can automatically mark the patient's statements that conform to the diagnostic provisions when doctors are having a conversation with patients. Meanwhile, the AI emotion recognition module can analyze the emotional features of the patient's voice when speaking and verify the consistency with the patient's self-reported emotions. If the system finds that the patient says "I'm in a okay mood" but the voice feature is "sad", it will uninterferently prompt the doctor to investigate further. This enhances the structuring and standardization of diagnosis, which is particularly helpful for junior doctors.

3.2 Quantitative assessment of symptom Severity

Quantifying symptoms is the basis for precisely evaluating therapeutic effects. AI provides objective indicators based on behavioral performance. In computerized cognitive tests, patients complete an emotional Stroop task or a reward learning task (PRT), and the AI records the degree of variation and error types in their responses. The typical manifestations of patients with depression are: prolonged attention span to negative stimuli and a reduced learning rate of positive feedback in reward learning. By calculating the behavioral parameters in the task state, the AI model can output a continuous score ranging from 0 to 100 as a supplement to HAM-D or MADRS. This phenotypic assessment is insensitive to the subjective reporting bias of patients and is particularly suitable for evaluating the short-term cognitive improvement effect of psychotherapy.

3.3 AI-assisted Differential Diagnosis

3.3.1 Differential Diagnosis Based on Neuroimaging

Neuroimaging provides biological evidence at the structural and functional levels for differential diagnosis. In terms of structure, voxel-based morphological analysis (VBM) revealed that the gray matter volume in the hippocampus and prefrontal cortex of patients with depression decreased[4] .AI can automatically segment these brain regions and measure their volumes, assisting in distinguishing between depression and depressive episodes of bipolar disorder. Functionally, abnormal network functional connectivity in the default mode of resting-state fMRI is a typical feature of depression. The AI network model based on graph theory analysis can calculate the clustering coefficient and the shortest path length of the brain network, providing quantitative indicators for distinguishing depression from anxiety disorders and even subtype classification. Although it has not yet entered clinical routine, the AUC of AI-assisted imaging diagnosis has reached 0.85-0.90.

3.3.2 Identification based on peripheral biological markers

Metabolomics and proteomics generate massive amounts of data, and AI is an essential tool for analyzing these data. By analyzing the metabolite profiles in blood, urine or saliva (such as tryptophan-kynurenine pathway metabolites), inflammatory factors (such as IL-6, TNF-α) and neurotrophic factors (BDNF), AI models can construct "biomarker fingerprints". For instance, the Support Vector Machine (SVM) model can distinguish depression from depressive syndrome caused by physical illness with an accuracy rate of approximately 80% by screening out specific threshold combinations of IL-6 and BDNF. In addition, AI can also identify biomarker groups related to specific endophenotypes, providing a basis for subsequent treatment choices, which has already taken on the initial form of individualized medicine.

3.3.3 Comprehensive identification based on multimodal data

Real clinical decisions are ultimately based on multi-source information. The AI integration model structurally integrates clinical variables (symptom patterns, age of onset, family history), neuroimaging indicators, biomarkers and behavioral data. The study employed unsupervised learning and successfully classified patients with depression into three biological subtypes: the subtype mainly characterized by impaired neural plasticity, the subtype mainly characterized by immune and inflammatory dysregulation, and the subtype mainly characterized by psychosocial cognitive bias. This breaks through the traditional "one-size-fits-all" diagnostic classification, providing rich information far beyond the simple "yes/no" diagnosis for clinical decision-making, and is a crucial step towards realizing the vision of "divide and treat" in psychiatry.

4. APPLICATION OF AI IN THE TREATMENT OF DEPRESSION

Treatment is the core link in the clinical management of depression. The application of AI covers two major fields: biology and psychology, aiming to achieve individualized, precise and accessible intervention strategies.

4.1 Drug Therapy

4.1.1 Medication consultation and decision support

Clinical medication selection often follows a "trial and error" approach, while AI can provide "extrapolation based on experience" support. By establishing a database that includes patients' genotypes, demographic characteristics, comorbidities and past medication history, decision support systems based on logistic regression or XGBoost algorithms can recommend preferred drugs for scenarios such as "young women experiencing their first depressive episode". In addition, the knowledge graph system integrated with the latest clinical guidelines can provide real-time evidence-based advice through question-and-answer interaction, reducing the time for information retrieval.

4.1.2 Therapeutic effect prediction and individualized medication

Predicting the therapeutic effect in advance can significantly reduce patients' suffering and the waste of medical resources. Based on the symptom change rate and early adverse reactions within two weeks of treatment, combined with the resting-state EEG frontal lobe alpha lateralization index before treatment, the AI model can predict with high accuracy whether clinical remission will be achieved after four weeks. In addition, regarding commonly used SSRI drugs, AI models based on genomic data (such as 5-HTTLPR polymorphism) and functional magnetic resonance imaging (fMRI) brain region activation patterns have begun to be used to predict individualized efficacy, and it is expected to gradually achieve "speaking with data rather than trial and error based on experience".

4.1.3 Adverse reaction monitoring

AI has enabled pharmacovigilance to shift from "passive reporting" to "active early warning". On the one hand, NLP systems that analyze social media and EMR can automatically identify and aggregate side effect events such as sexual dysfunction and weight gain that patients may be reluctant to report voluntarily[5] .On the other hand, the movement patterns related to prolonged QTc intervals of the heart or sedentary inability monitored in real time by wearable devices, after being analyzed by deep learning models, can issue warnings several hours before serious events occur. This significantly enhances the safety of long-term medication.

4.2 Psychotherapy

4.2.1 Digital Assistance in cognitive Behavioral Therapy

Psychotherapy, especially cognitive behavioral therapy (CBT), is widely regarded as an effective intervention for treating depression. However, the limited number of well-trained therapists restricts access to psychological services in many regions. Ai-supported digital psychotherapy platforms offer a possible approach to expanding mental health services. These systems can assist patients in completing structured CBT exercises, such as recording negative thoughts, identifying cognitive distortions, and practicing behavioral activation strategies[6]. Compared with traditional face-to-face therapy, digital AI-assisted intervention has advantages such as higher accessibility, flexible usage time, and the ability to provide continuous support during clinical consultations. For patients with mild to moderate depressive symptoms, such tools can serve as supplementary resources. However, psychotherapy is not merely a structured procedure; It also involves emotional understanding, trust building and professional empathy. Therefore, the application of AI in psychotherapy should focus on supporting therapists and improving accessibility rather than attempting to completely replace human psychological intervention.

4.2.2 Conversational AI psychotherapy

The emergence of large language models has promoted the development of conversational AI systems that can provide interactive psychological support. These systems can interact with users through conversations, provide emotional responses, and offer basic psychological guidance. Compared with human therapists, AI has advantages such as being available 24/7, having a non-judgmental attitude, and being able to explain infinitely repeatedly. Preliminary randomized controlled trials have shown that for mild to moderate depression, AI-driven treatment programs can significantly reduce the PHQ-9 score within 6 to 8 weeks, and the dropout rate is lower than that of traditional psychotherapy[7].Of course, its ability to handle complex traumas or crisis intervention still needs to be improved.

4.2.3 Monitoring and feedback on treatment compliance

Treatment compliance is the cornerstone of therapeutic effect. AI conducts remote monitoring through multimodal behavior analysis. For instance, when a patient fails to complete the daily mindfulness practice as planned, the app will issue a silent vibration reminder through the wearable bracelet. If the patient does not open the application for three consecutive days, the system will analyze whether the GPS location entropy has decreased (prompt social avoidance), and automatically send a warning to the therapist team, who will proactively contact the patient. This closed-loop feedback system significantly improves the completion rate of "homework", thereby enhancing the real-world effect of CBT.

4.3 Physical Therapy

4.3.1 Optimization of transcranial magnetic stimulation parameters

Traditional repetitive transcranial magnetic stimulation (rTMS) adopts the "standard protocol", but patients' responses to the frequency, intensity and target of the stimulation vary greatly. AI achieves personalized treatment through two core technologies: First, neural navigation optimization - based on the 3T-MRI structural image of an individual patient, the deep learning model can automatically segment and precisely identify the individual coordinates of the standard target, the left dorsolateral prefrontal lobe (DLPFC) [8].Second, parameter adaptive adjustment - In the first treatment, the motor evoked potential (MEP) is collected in real time. The reinforcement learning model can dynamically adjust the stimulation intensity to stably maintain the excitability of the target cortex with the lowest energy consumption. Preliminary evidence shows that the AI-optimized rTMS scheme can increase the response rate from the standard 50%-60% to over 70%.

4.3.2 Prediction of electroconvulsive therapy effects

Electroconvulsive therapy (ECT) has a significant effect on severe and refractory depression, but it has cognitive side effects and a relatively high recurrence rate. Based on high-resolution structural MRI and resting-state fMRI data before treatment, AI (especially the graph convolutional network GCN) can construct individualized brain structure-functional connectomes. Studies have confirmed that the strength of the connection between the prefrontal lobe and the limbic system (especially the anterior cingulate gyrus and the hippocampus) at baseline is a key feature for predicting the efficacy of ECT[9]. By leveraging these features, the AI model can divide patients into two groups: "expected significant improvement" and "expected limited effect", with an accuracy rate exceeding 80%. This helps to avoid unnecessary treatment for ineffective patients and achieve precision medicine.

5. APPLICATION OF AI IN THE PROGNOSIS MANAGEMENT AND RECURRENCE PREVENTION OF DEPRESSION

The 6-month recurrence rate of depression is as high as 20% to 30%, and the lifetime recurrence rate exceeds 50%. The potential of AI in preventing recurrence is reflected in the shift from "intermittent follow-up" to "continuous monitoring".

5.1 Remote health monitoring and follow-up management

By leveraging passive data from smartphones and wearable devices, AI can achieve "scalable continuous monitoring". The system can continuously assess the patient's mental state without the patient's active input. For instance, by analyzing features such as the patient's "emotional tendency of the text content that actively calls the language model", "coefficient of variation of daily steps", and "peak time of heart rate at night", the AI model can construct an individual's "health baseline"[10]. When new data deviates from the baseline for 48 consecutive hours, such as a 30% reduction in step count and a 50% decrease in social application usage, the system will automatically trigger a lightweight intervention or alert the doctor through the EMR interface. This low-burden and high-density follow-up helps to detect signs of re-ignition at an early stage.

5.2 Recurrence risk prediction model

The traditional recurrence risk depends on limited variables such as "the number of previous episodes". AI models can elevate risk prediction to dynamic and personalized probability assessment. Deep learning models based on survival analysis (such as DeepSurv) can integrate patients' long-term clinical history (the time and duration of each episode, treatment response), environmental stress events in life, such as analyzing social media or diary texts through NLP, as well as real-time physiological-behavioral markers, such as reduced HRV and fragmented sleep. Output a "recurrence risk curve" that varies over time[11]. For instance, after experiencing a work stress event, the model can prompt in real time: "The recurrence risk in the next two weeks is moderately high (35%). It is recommended to add one more supportive consultation and continue to monitor sleep." This provides a time window for achieving precise prevention.

5.3 Patient self-management support system

The first line of defense against recurrence is the patient themselves. The self-management system empowered by AI has transformed from a "passive tool" to an "active partner". Systems based on reinforcement learning can learn the preferences and response patterns of individual patients. For instance, if a patient's compliance with "guided meditation" is much higher than that with "physical exercise" when they are in a low mood, the system will give priority to recommending meditation[12]. In addition, personalized psychological education resources driven by large language models can dynamically generate corresponding psychological education short essays or behavioral activation suggestions (such as "try organizing a drawer") based on the patient's current cognitive patterns (such as whether there is "disastrous thinking"). The system can also record the patient's coping strategies during emotional peaks and automatically build an individual's "antidepressant toolkit" for quick access when feeling down in the future.

6. CONCLUSION

The role of AI in the clinical management of depression should be positioned as "enhancing intelligence" rather than "replacing intelligence". The ideal prospect is to build an integrated model of "human-machine collaboration" : AI is responsible for large-scale screening, continuous monitoring, structured intervention and automated advice, liberating human doctors and therapists to focus on establishing therapeutic alliances, handling complex crises, conducting in-depth psychotherapy and making final clinical judgments. With the development of multimodal models, federated learning and interpretability technologies, a new era of mental health that is more predictive, preventive, personalized and participatory is bound to arrive. As future clinical workers, we should actively participate in this transformation, embrace the benefits brought by technology while prudently managing its risks, and ultimately make technology serve human well-being and dignity.

REFERENCES

[1] Lu JM, Xu XM, Huang YP, et al. Prevalence of depressive disorders and treatment in china: a cross-sectional epidemiological study[J]. Lancet Psychiatry, 2021, 8(11): 981-990.

[2] Lou T, Liu ZH, Zhang GF. Progress in the application of artificial intelligence-based MRI in depression[J]. Chinese Journal of Magnetic Resonance Imaging, 2026, 17(03): 117-124.

[3] Francese R, Attanasio P. Emotion detection for supporting depression screening[J]. Multimedia Tools and Applications, 2023, 82(9): 12771-12795.

[4] Che QY, Sun YL, Jin J, et al. Application of neurofeedback-enhanced positive emotion in the treatment of depression[J]. Advances in Psychological Science, 2024, 32(02): 342-363.

[5] Peng LP, Wang K. Research progress of artificial intelligence in comprehensive management of patients with depression[J]. Psychology Monthly, 2025, 20(20): 225-227.

[6] Deng SL, Zhu QY, Liu LY, et al. Evaluation of the effectiveness of online peer mental health support for users in human-AI interaction contexts[J]. Journal of Modern Information, 2026, 46(04): 80-91.

[7] Wang XH, Liu JY, Zhang ZC, et al. Research progress on the application of digital therapy in the treatment of patients with depression[J]. Chinese Journal of Medical Management Sciences, 2025, 15(06): 95-101.

[8] ZHANG Z, LI G, XU Y, et al. Application of Artificial Intelligence in the MRI Classification Task of Human Brain Neurological and Psychiatric Diseases: A Scoping Review[J/OL]. Diagnostics (Basel), 2021, 11(8): 1402 [2026-01-16].

[9] Kellner CH, Kaicher DC, Banerjee H, et al. Depression severity in electroconvulsive therapy (ECT) versus pharmacotherapy trials[J]. J ECT, 2015, 31(1): 31-33.

[10] TOROUS J, BUCCI S, BELL I H, et al. The growing field of digital psychiatry: current evidence and the future of apps, social media, chatbots, and virtual reality[J]. World Psychiatry, 2021, 20(3): 318-335.

[11] Han JL, Feng L. Research progress on the application of artificial intelligence in the field of depression[J]. Beijing Medical Journal, 2020, 42(04): 317-319+322.

[12] Zhao J, Chang H. Research progress of digital health technology in self-management of patients with multiple sclerosis[J]. Chinese Nursing Management, 2025, 25(12): 1908-1913.